HBIO(HBIO)
HBIO
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $89M | $94M | $87M |
| Low | $88M | $93M | $86M |
| High | $89M | $95M | $87M |
| EBITDA Avg | $-7M | $-7M | $-7M |
| Low | $-7M | $-8M | $-7M |
| High | $-7M | $-7M | $-7M |
| EBIT Avg | $-13M | $-14M | $-13M |
| Low | $-13M | $-14M | $-13M |
| High | $-13M | $-14M | $-13M |
| Net Income Avg | $-3M | $2M | — |
| Low | $-3M | $1M | — |
| High | $-3M | $3M | — |
| EPS Avg | $-0.70 | $0.44 | — |
| Low | $-0.71 | $0.25 | — |
| High | $-0.69 | $0.63 | — |
| Analysts (Rev / EPS) | 1 / 1 | 2 / 2 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $22M | $25M | $22M | $23M | $23M | $26M |
| Low | $22M | $24M | $22M | $22M | $23M | $25M |
| High | $22M | $25M | $22M | $23M | $23M | $26M |
| EBITDA Avg | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M |
| Low | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M |
| High | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M |
| EBIT Avg | $-3M | $-4M | $-3M | $-3M | $-3M | $-4M |
| Low | $-3M | $-4M | $-3M | $-3M | $-3M | $-4M |
| High | $-3M | $-4M | $-3M | $-3M | $-3M | $-4M |
| Net Income Avg | $-1M | $475,230 | $-1M | $905,200 | $905,200 | $2M |
| Low | $-1M | $474,551 | $-1M | $903,932 | $903,932 | $2M |
| High | $-1M | $475,909 | $-1M | $906,467 | $906,467 | $2M |
| EPS Avg | $-0.27 | $0.10 | $-0.23 | $0.20 | $0.20 | $0.38 |
| Low | $-0.27 | $0.10 | $-0.23 | $0.20 | $0.20 | $0.38 |
| High | $-0.27 | $0.11 | $-0.23 | $0.20 | $0.20 | $0.38 |
| Analysts (Rev / EPS) | 2 / 1 | 2 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |